Ranbaxy, Cipla bid for Merck KGaA's generics branch

03/13/2007 | Financial Express (India), The

Ranbaxy Laboratories Ltd. and Cipla Ltd., two Indian drugmakers, offered bids for the German Merck's generic drugs unit, but Dr Reddy's Laboratories did not by deadline. Although the bids were not disclosed, the Merck KGaA generics unit was estimated to be worth $5.3 billion. Sources said the auction is likely to be very competitive, as several other firms are eyeing the unit as well.

View Full Article in:

Financial Express (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR